简介:
- 作者: Chunyi Li, Hui Li, Xuejiao Men, Yuge Wang, Xinmei Kang, Mengyan Hu, Xiaotao Su, Shisi Wang, Danli Lu, Shishi Shen, Huipeng Huang, Xiaohui Deng, Yuxin Liu, Lei Zhang, Wei Cai, Aimin Wu, Zhengqi Lu
- 杂志: CNS Neuroscience & Therapeutics
- 出版日期: 2025 Jan 24
摘要
ABSTRACT
Aims
The aim of this study is to investigate the role of glymphatic function of cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL), the most common monogenic small vessel disease caused by NOTCH3 mutation, and to explore potential therapeutic strategies to improve glymphatic function.
Methods
We assessed glymphatic influx and efflux function in CADASIL mouse models (Notch3 R170C) and correlated these findings with brain atrophy in CADASIL patients. We also investigated the underlying mechanisms of glymphatic impairment, focusing the expression of AQP4 in astrocytic endfeet.
Results
CADASIL mouse exhibited both impaired glymphatic influx and efflux, which impedes waste clearance and promotes brain senescence. In accordance, brain atrophy in CADASIL patients is associated with perivascular space enlargement, indicating that glymphatic impairment contributes to advanced brain senescence in CADASIL. The glymphatic malfunction in CADASIL is attributed to diminished AQP4 expression in astrocytic endfeet, which is the core mediator of glymphatic activity. Mechanistically, AQP4 expression is regulated by NOTCH3‐RUNX1‐CMYB signaling. Reinforcing AQP4 expression in astrocytes by AAV‐based therapy resumes the glymphatic functions in CADASIL mice, which further prevents brain senescence.
Conclusion
We propose that to improve glymphatic function by reinforcing AQP4 expression is a promising therapeutic strategy in CADASIL.
Keywords: AQP4, brain senescence, CADASIL, glymphatic system
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。